Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Bond markets have quietly rewritten the rulebook, with the US 30 year Treasury yield sitting around a 25 year high and reshaping what counts as a safe return. Higher risk free rates can punish stretched balance sheets, yet they can also reprice long term liabilities in interesting ways. This piece walks through three stocks exposed to that rate shock, and why their reaction to it deserves a closer look. The three stocks below are just a sample set, while the full screen on Simply Wall St...
Chesnara PLC (LSE:CSN) saw operating capital generation jump 79% to £96 million in the first half. CEO Steve Murray also highlighted the group's 185% solvency coverage ratio and an active acquisition pipeline. Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) has raised £1.3 million to push forward its CNS drug pipeline. That includes trials for alcohol use disorder and addiction treatments. hVIVO PLC (AIM:HVO) has bought CRS Berlin to expand into dermatology and women's health trials. The CEO says it opens up new markets and cross-selling opportunities in Germany. Gelion PLC (AIM:GELN, OTC:G
Chesnara PLC (LSE:CSN) CEO Steve Murray spoke with Proactive about first-half performance, including a 79% rise in operating capital generation to £96 million, progress integrating Chesnara Life and the outlook for further acquisitions. Murray said the strong capital generation reflected positive underlying performance, management actions like balance-sheet optimisation and reinsurance, and a significant contribution from Chesnara Life, formerly HSBC Life UK, which joined the group at the end of January. On integration, Murray said Chesnara has announced a combined UK leadership team and begun
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.